<DOC>
	<DOCNO>NCT01312454</DOCNO>
	<brief_summary>The purpose study assess safety efficacy AL-59412C inject intravitreally relative Vehicle .</brief_summary>
	<brief_title>Safety Intraocular Pressure ( IOP ) Lowering Effect AL-59412C</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Diagnosis primary openangle glaucoma ocular hypertension . Retinal pathology ( eg , retinal degeneration ) , anterior ischemic optic neuropathy , vascular occlusion result poor vision study eye . Able discontinue intraocularlowering ( IOP ) medication accord minimum washout period , base upon class medication . Mean wash IOP ≥ 24 millimeter mercury ( mmHg ) ≤ 36 mmHg 8 AM study eye two separate Eligibility Visits . Other protocoldefined inclusion criterion may apply . Lens/corneal/vitreal opacity prevent adequate posterior segment visualization study eye . Current recent ( within 30 day ) use drug may prolong QT interval . Poor vision result advanced glaucoma study eye . Intraocular surgery within past 6 month study eye . Ocular laser surgery within past 3 month study eye . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>intravitreal injection</keyword>
	<keyword>intraocular pressure</keyword>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
</DOC>